{
  "Variants Include": [
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_006209.4:c.6057G>A",
          "cDNA Change": {
            "transcript": "NM_006209.4",
            "ref": "G",
            "alt": "A",
            "position": "6057"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "S",
            "position": "2019"
          },
          "Description in input context": "G2019S and I2020T have approximately 2-fold lower and 6-fold higher ATP affinity, respectively, than wild-type LRRK2."
        },
        {
          "HGVS": "NM_006209.4:c.6058I>T",
          "cDNA Change": {
            "transcript": "NM_006209.4",
            "ref": "I",
            "alt": "T",
            "position": "6058"
          },
          "Protein Change": {
            "ref": "I",
            "alt": "T",
            "position": "2020"
          },
          "Description in input context": "G2019S and I2020T have approximately 2-fold lower and 6-fold higher ATP affinity, respectively, than wild-type LRRK2."
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0001704"
  },
  "Experiment Method": [
    {
      "Assay Method": "ATP Affinity Binding Assay",
      "Material used": {
        "Material Source": "Recombinant LRRK2 protein",
        "Material Name": "LRRK2",
        "Description": "ATP affinity was measured using recombinant LRRK2 protein expressed in HEK293 cells."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_006209.4:c.6057G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "reduced ATP binding affinity",
          "Result Description": "G2019S shows 2-fold lower ATP affinity compared to wild-type LRRK2."
        },
        {
          "Variant": "NM_006209.4:c.6058I>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "increased ATP binding affinity",
          "Result Description": "I2020T shows 6-fold higher ATP affinity compared to wild-type LRRK2."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed in each experiment."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each protein sample was tested in triplicate."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type LRRK2 protein was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "A protein sample without ATP was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "Yes",
        "Counts": "2"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "Yes",
        "Counts": "1"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "ANOVA was used to compare ATP affinities between variants and wild-type."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "ATP binding affinity within 1.5-fold of wild-type values.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "ATP binding affinity below 0.5-fold of wild-type values.",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}